Your session is about to expire
← Back to Search
Gabapentin for Spinal Cord Injury Neurorecovery
Study Summary
This trial will test whether gabapentin can help with neurorecovery, and whether it is feasible to conduct a well-designed study on the efficacy of the intervention in the future.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 88 Patients • NCT03012815Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was taking gabapentinoids when I got injured.I have a spinal cord injury due to trauma.I am 18 years old or older.I had a severe head injury with a low coma score.I agree to start the study medication within 5 days after my injury.My spinal cord injury ranges from complete to incomplete.I understand the information given to me and can communicate my decision.
- Group 1: Low dose
- Group 2: Medium dose
- Group 3: Control
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals is the study limited to in its current iteration?
"Yes, the information on clinicaltrials.gov states that this ongoing medical trial is inviting potential candidates to join in their research initiative. This study was first posted on March 14th 2022 and its most recent update took place on March 29th 2022. Currently, 42 patients are being recruited at one site for this project."
Has Gabapentin been given the greenlight by the FDA?
"Gabapentin's safety has been affirmed through Phase 4 trials, thus it was given a rating of 3."
Are there any vacancies in this trial for interested participants?
"Per the records published on clinicaltrials.gov, candidates are being sought to participate in this study which was originally posted March 14th and recently amended on 29th of same month."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger